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ORIGINAL INVESTIGATION
Effects of 1 year of exercise training 
versus combined exercise training and weight 
loss on body composition, low-grade 
inflammation and lipids in overweight patients 
with coronary artery disease: a randomized trial
Lene Rørholm Pedersen1,2* , Rasmus Huan Olsen1, Christian Anholm3, Arne Astrup4, Jesper Eugen‑Olsen5, 
Mogens Fenger6, Lene Simonsen7, Rosemary L. Walzem8, Steen Bendix Haugaard9 and Eva Prescott1
Abstract 
Background: Dyslipidaemia and low‑grade inflammation are central in atherogenesis and linked to overweight and 
physical inactivity. Lifestyle changes are important in secondary prevention of coronary artery disease (CAD). We com‑
pared the effects of combined weight loss and interval training with interval training alone on physical fitness, body 
composition, dyslipidaemia and low‑grade inflammation in overweight, sedentary participants with CAD.
Methods: Seventy CAD patients, BMI 28–40 kg/m2 and age 45–75 years were randomised to (1) 12 weeks’ aerobic 
interval training (AIT) at 90% of peak heart rate three times/week followed by 40 weeks’ AIT twice weekly or (2) a low 
energy diet (LED) (800–1000 kcal/day) for 8–10 weeks followed by 40 weeks’ weight maintenance including AIT twice 
weekly and a high‑protein/low‑glycaemic load diet. Effects of the intervention were evaluated by physical fitness, 
body weight and composition. Dyslipidaemia was described using both biochemical analysis of lipid concentrations 
and lipoprotein particle subclass distribution determined by density profiling. Low‑grade inflammation was deter‑
mined by C‑reactive protein, soluble urokinase‑type plasminogen activator receptor and tumour necrosis factor α. 
Effects on continuous outcomes were tested by mixed‑models analysis.
Results: Twenty‑six (74%) AIT and 29 (83%) LED + AIT participants completed the study. At baseline subject included 
43 (78%) men; subjects averages were: age 63 years (6.2), body weight 95.9 kg (12.2) and  VO2peak 20.7 mL  O2/kg/min 
(4.9). Forty‑six (84%) had pre‑diabetes (i.e. impaired fasting glucose and/or impaired glucose tolerance). LED + AIT 
reduced body weight by 7.2 kg (− 8.4; − 6.1) and waist circumference by 6.6 cm (− 7.7; − 5.5) compared to 1.7 kg 
(− 0.7; − 2.6) and 3.3 cm (− 5.1; − 1.5) after AIT (within‑group p < 0.001, between‑group p < 0.001 and p = 0.018, 
respectively). Treatments caused similar changes in  VO2peak and lowering of total cholesterol, triglycerides, non‑HDL 
cholesterol and low‑grade inflammation. A shift toward larger HDL particles was seen following LED + AIT while AIT 
elicited no change.
Conclusions: Both interventions were feasible. Both groups obtained improvements in  VO2peak, serum‑lipids and 
inflammation with superior weight loss and greater central fat loss following LED + AIT. Combined LED induced 
weight loss and exercise can be recommended to CAD patients.
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
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Introduction
Physical inactivity and obesity, abdominal obesity in par-
ticular, are known risk factors in coronary artery disease 
(CAD). Lifestyle interventions to reduce body weight and 
increase physical activity are cornerstones of secondary 
CAD prevention [1–3] Exercise-based cardiac rehabili-
tation programmes lower hospital admissions, total and 
cardiovascular mortality [4]. The EUROASPIRE IV study, 
evaluating the secondary prevention effort in CAD in 
Europe from 2012 to 2013, showed that 82.1% of CAD 
patients were overweight or obese (BMI > 25  kg/m2) 
and 58.2% were centrally obese based on waist circum-
ference. These numbers have gradually increased com-
pared to previous EUROASPIRE cohorts dating back to 
1995–1996. In the same population 60% of the patients 
reported little or no physical activity and poor metabolic 
risk factor control concerning dyslipidaemia and type 2 
diabetes was described [5]. Thus, effective and sustain-
able cardiac rehabilitation strategies are needed.
Dyslipidaemia and increased levels of low-grade 
inflammation are linked to obesity and physical inactiv-
ity [1, 6, 7] and related to excess cardiovascular risk in 
healthy population [8–12] and to a poor prognosis in 
patients with CAD [13–15]. Both exercise and weight 
loss interventions have been shown to improve dyslipi-
daemia [16–19] and reduce low-grade inflammation [20–
22]. Atherogenic lipoproteins in the intima and media of 
the arterial wall elicit an inflammatory response that ini-
tiate and promote atherosclerotic plaque [6]. The amount 
of LDL-C and HDL-C in blood is used to monitor choles-
terol-lowering treatment [1]; however, lipoprotein den-
sity profiling to measure lipoprotein density subclasses 
is used in the current report to give a more precise risk 
estimation by taking into account the contribution of 
small, dense atherogenic lipoprotein particles [23]. In 
the present paper low-grade inflammation is described 
using C-reactive protein (CRP), tumour necrosis factor 
α (TNFα) and soluble urokinase-type plasminogen acti-
vator receptor (suPAR). CRP is a well-known marker of 
low-grade inflammation [12] while TNFα is important 
in the link between obesity, sedentary behaviour, ath-
erosclerosis and insulin resistance [6]. The more recently 
described suPAR is believed to play a role in the develop-
ment of the unstable plaque [24].
A recent systematic review showed that aerobe exer-
cise training for 12  weeks or more improved body 
composition, metabolic outcome and physical fitness 
in individuals with metabolic syndrome [25] and in 
patients with type 2 diabetes aerobic exercise at high 
intensities improves physical fitness and glycaemic 
control [26]. A 12-week study comparing diet-induced 
weight loss, exercise-induced weight loss and exercise 
without weight loss in healthy overweight populations 
found that all interventions improved body compo-
sition. The greatest body composition improvement 
was seen in the weight loss groups, while physical fit-
ness was improved in the exercise group [27]. This is 
in accordance with previously reported results in the 
present trial demonstrating that a rapid 10% weight 
loss using a low energy diet (LED) was superior to a 
12–week aerobic interval training (AIT) programme in 
reducing body weight, body fat mass, waist circumfer-
ence and lipid atherogenicity. Low-grade inflammation 
was largely unchanged in both groups. Exercise training 
was superior to weight loss alone in improving physical 
fitness [28, 29].
Cardiac rehabilitation programmes are often short-
term interventions and sustaining the effects obtained 
is a major challenge. A long-term comparison of weight 
loss induced by exercise, caloric restriction or a com-
bined intervention in a healthy population showed 
that a combination of weight loss and exercise pro-
vides greater improvement in physical function than 
either intervention alone [30]. A 2009 study in which 
74 participants with CAD were randomised to either 
5 months of high-calorie-expenditure exercise or a less 
intense standard cardiac rehabilitation exercise found 
that intense exercise caused a greater weight loss and 
a more favourable cardiometabolic risk profile [31]. 
However, there is a paucity of short- and long-term tri-
als addressing lifestyle intervention and maintenance 
programmes in CAD patients [1, 32].
To address this gap we wish to describe the effect 
of a long-term 1-year intervention. The current paper 
details effects on physical fitness and metabolic risk 
described using body composition, dyslipidaemia and 
low-grade inflammation following the entire 1-year 
intervention in the randomised CUT IT trial. The CUT 
IT trial compared the effects of a combined weight loss 
and aerobic interval training (AIT) programme to AIT 
alone in a randomised design. We hypothesized that a 
strategy of weight loss followed by AIT would be supe-
rior to AIT alone to achieve long-term success.
Trial registration NCT01724567, November 12, 2012, retrospectively registered (enrolment ended in April 2013).
Keywords: Aerobic interval training, Weight loss, Secondary prevention, Coronary artery disease, Dyslipidaemia, Low‑
grade inflammation, Dyslipidaemia
Page 3 of 13Pedersen et al. Cardiovasc Diabetol          (2019) 18:127 
Methods
Study design
Seventy participants were consecutively enrolled and 
randomised 1:1 to either AIT or low energy diet weight 
loss and AIT (LED + AIT). Inclusion criteria were sta-
ble CAD diagnosed > 6  months prior to inclusion, age 
45–75  years and BMI 28–40  kg/m2. Exclusion crite-
ria were known diabetes or diabetes diagnosed at the 
screening visit, other severe heart disease (i.e. heart 
failure EF < 35%, severe or moderate valve disease, main 
stem stenosis and arrhythmias or ischaemia revealed by 
the cardiopulmonary exercise test and 2. or 3. degree 
AV block not protected by a pacemaker) or severe co-
morbidity (i.e. chronic pulmonary disease, active can-
cer or severe kidney failure). Furthermore, candidates 
who participated in organised sports more than twice 
weekly or had experienced a significant weight loss or 
gain (> 5%) more than 3 months prior to the screening 
visit were excluded.
1. AIT: 12  weeks’ supervised AIT three times weekly 
followed by 40 weeks’ AIT twice weekly. Each exer-
cise session was preceded by a 10-minute warm-up 
on stairs or an exercise bike followed by high inten-
sity interval training on an exercise bike. The high 
intensity intervals (85–90% of  VO2peak, Borg scale 
17–18) lasted between 1 and 4 min, to achieve a total 
of 16  min, separated by active pauses (65–70% of 
 VO2peak) of 1- and 3-min duration. The total dura-
tion of each training session was 48  min including 
the warm-up. Physiotherapists with experience in 
cardiac rehabilitation instructed the participants and 
supervised all training session. Training intensity was 
monitored with heart rate monitors and perceived 
exertion using the Borg Scale [33]. Additional file 1: 
Figure S1 shows a heart rate curve from an exercise 
session to illustrate the exercise intervention.
2. LED + AIT: 8–10  weeks’ LED (800–1000  kcal/day, 
the Cambridge Weight Plan, Northants, UK) fol-
lowed by 2–4 weeks’ transition to a maintenance diet 
to avoid examining the participants in a catabolic 
state. The last 40  weeks included the maintenance 
diet and AIT twice weekly. The maintenance diet was 
a low glycaemic load diet achieved by slightly higher 
protein content and focus on low glycaemic index 
carbohydrates as described in the DIOGenes study 
[34]. The LED and the maintenance diet were super-
vised by experienced dieticians.
A more comprehensive description of study design, 
population and interventions was published previously 
[35].
Body weight and composition
Body weight, hip and waist circumference were deter-
mined in the morning after a 10-h fast. Waist circum-
ference was measured halfway between the lower rib 
and the iliac crest and hip circumference at the maximal 
gluteal protuberance and calculated as an average of two 
consecutive measurements. Fat mass and fat free mass 
were estimated using a whole-body dual X-ray absorpti-
ometry scan (Lunar DPX-IQ, GE Lunar Corp, Madison, 
WI, USA).
Physical fitness and self‑reported physical activity
VO2peak was assessed by a stepwise cardiopulmonary 
exercise test (CPET) using a bicycle ergometer (Via Sprint 
150 P, Ergoline, Bitz, Germany) with breath-by-breath 
gas exchange measurements (Jaeger, MasterScreenCPX, 
Cardinal Health, Wurzburg, Germany). The participants 
completed a CPET at the screening visit (Fig. 1) to obtain 
familiarisation to the test. Criteria for  VO2peak were 
levelling off of  VO2 despite increasing workload or peak 
respiratory exchange ratio (peakRER) > 1.05.  VO2peak 
and peakRER were calculated as the mean of the six high-
est consecutive five-second measurements of  VO2 and 
 VO2/VCO2 before exercise termination.  VO2peak was 
expressed as:  VO2peaktotal (mL/min),  VO2peakbw (mL/
kg body weight/min) and, to account for changes in body 
composition,  VO2peakffm (mL/kg fat free  mass0.67/min) 
[36]. Peak heart rate determined during the CPET was 
used to monitor the exercise sessions.
The international physical activity questionnaire short 
form (iPAQ-SF) [37] was used at all visits and self-
reported physical activity duration and intensity was used 
to calculate weekly physical activity energy expenditure 
in kilocalories according to the IPAQ Research Commit-
tee recommendations [38]. The participants were asked 
to include the supervised exercise sessions.
Lipids and density profiling
Blood samples were taken in the morning after a 
10-hour overnight fast. Plasma lipids (i.e. total choles-
terol, high-density lipoprotein cholesterol (HDL-C) and 
triglycerides) were analysed immediately at the hos-
pital laboratory. Low-density lipoprotein cholesterol 
(LDL-C) was calculated using Friedewald’s equation 
(LDL-C = total cholesterol − HDL-C + 0.45 × triglyc-
erides). One subject was excluded due to triglycer-
ides > 4.5  mmol/L [1]. Total cholesterol/HDL-C-ratio 
and non-HDL-C = total cholesterol − HDL-C were 
calculated. To further describe the atherogenicity of 
the lipoproteins additional information on lipoprotein 
particle density and subclass distribution were obtained 
using isopycnic density profiling of lipoproteins 
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pre-stained with a lipophilic fluorescent probe as we 
have described previously [28]. In that analysis lipo-
protein amount is measured by area under the curve 
(AUC). LDL and HDL particle size were estimated 
based in the average particle size for each subfraction 
and the percentage each subfraction constituted of 
total LDL or HDL, respectively.
Inflammatory markers
Tumour necrosis factor α (TNFα) was determined using 
an enzyme-linked immunosorbent assay (ELISA, DRG 
instruments Marburg, Germany). Soluble urokinase plas-
minogen activator receptor (SuPAR) was analysed using 
 suPARnostic® ELISA (ViroGates, Copenhagen, Den-
mark). C-reactive protein (CRP) was determined using a 
Fig. 1 Inclusion and course of the study. AIT, Aerobic interval training, LED, Low energy diet. ITT: Intention‑to‑treat including all participants 
attending the follow‑up. PP: per protocol. PP 12‑weeks: including all participants who met per protocol criteria. PP 1 year: including all participants 
who completed the 12‑week intervention per protocol and attended the one‑year follow‑up
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high-sensitivity assay ELISA with a lower detection limit 
of 0.2  mg/L. All kits were used according to the manu-
facturer instructions. For intra- and inter-assay variation 
please see Ref. [28].
Blood pressure
Blood pressure was measured in the morning > 18 h after 
the latest exercise session in the supine position after 
10 min’ rest as an average of the last two of three consec-
utive measurements on the dominant arm using an oscil-
lometric blood pressure monitor (CARESCAPE V100, 
GE Healthcare, Horten, Norway).
Hospital Anxiety and Depression Scale (HADS) 
and symptoms
Anxiety and depression were evaluated by the self-assess-
ment Hospital Anxiety and Depression Scale (HADS) 
separated into anxiety (HADS-A) and depression 
(HADS-D) sub-scales [39].
Intention‑to‑treat and per protocol analyses
All participants were invited and encouraged to attend 
the 12-week follow-up, the 40-week maintenance period 
and 1-year follow-up independently of adherence to pro-
tocol. The main analyses presented are intention-to-treat 
including all patients who attended the baseline visit and 
the two follow-up visits at 12 and 52  weeks. Per proto-
col criteria of the 12-week intervention in the LED + AIT 
group were ≥ 5% weight loss whereas the AIT group 
required overall training attendance ≥ 60% and attend-
ance ≥ 50% the last 2 weeks of the intervention. Analyses 
including all participants who completed the 12-week 
intervention per protocol and attended the 1-year follow-
up are presented in Additional file 1.
Statistical analyses
The group sample size of 26 participants was calculated 
based on the primary end point of coronary velocity 
flow reserve; a further allowed drop-out rate of up to 
25% brought final study size to 70 participants [35]. At 
baseline categorical data are presented as number (per-
centage), normally distributed data as mean (SD) and 
non-normally distributed data as median (inter-quartile 
(IQ) range). Baseline comparisons were made using χ2 or 
Fischer’s exact test, unpaired t-test and Wilcoxon-rank 
test, respectively. Effects on continuous outcomes were 
tested by mixed-models with subject id as a random fac-
tor. Between-group differences were tested using models 
with group, visit and group*visit interaction as fixed fac-
tors, whereas within-group changes were tested in sepa-
rate models for each group. Logarithmic transformation 
was performed on TNFα, CRP and suPAR values ensur-
ing a normal distribution. The significance level was set 
to p < 0.05. Stata 13.1 software (StataCorp, College Sta-
tion, TX, USA) was used for all analyses.
Results
Population
A total of 70 participants were randomised, the 55 (79%) 
that completed the study are included in these intention-
to-treat analyses (Fig. 1). At baseline, 39 (76%) were male, 
mean age was 63  years (SD 6.2), median BMI was 31.4 
(IQ-range 29.8; 33.5). All participants were non-diabetic; 
however, 46 (84%) had pre-diabetes (i.e. impaired fast-
ing glucose and/or impaired glucose tolerance). Addi-
tional baseline data are presented in Table  1. Overall, 
participants were asymptomatic, well-controlled regard-
ing blood pressure and lipids and contemporarily treated 
with platelet inhibitors, statins, ACE-inhibitors/angio-
tensin receptor blockers and beta-blockers (Table  1). 
Baseline characteristics of the per protocol population 
did not differ from the intention to treat population 
(Additional file 1: Table S1). Participants who had altera-
tions made to their statin treatment were excluded from 
analyses of lipids and inflammatory markers. At 12 weeks 
this applied to one participant in the AIT group and at 
1 year one participant undergoing LED + AIT.
The main results presented are intention-to-treat anal-
yses of the changes from baseline to 1 year. Results from 
per protocol analyses are presented in Additional file  1 
and differences from intention-to-treat outcomes noted 
in the text. Results from the 12-week intervention are 
briefly mentioned where relevant.
Weight loss and body composition
The participants in the LED + AIT group lost 10.6% of 
body weight (p < 0.001) during the first 12  weeks’ inter-
vention while the AIT group lost a small but significant 
1.6% of body weight (p = 0.002). Both groups experi-
enced concomitant decreases in waist circumference and 
body fat mass; albeit, largest after LED (between-group 
p < 0.001) [29]. Despite a significant increase in body 
weight, body fat mass, waist circumference and waist/
hip-ratio in the LED + AIT group during the 40-week 
maintenance period body composition remained signifi-
cantly improved compared to baseline at 1 year. A non-
significant 0.5 kg (p = 0.060) decrease in fat free mass was 
seen in the intention to treat analysis. Per protocol analy-
sis showed a 0.6 kg decrease in fat free mass (p = 0.049) 
at 1  year in LED + AIT. However, from 12  weeks to 
1 year fat free mass in the LED + AIT group increased a 
non-significant 0.3 kg in both intention to treat and per 
protocol analyses (Table  2, Additional file  1: Table  S2). 
The AIT group maintained the effects on body com-
position obtained during the first 12 week. After 1 year 
LED + AIT was still superior to AIT alone with regards 
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to reducing body weight, body fat mass and waist cir-
cumference (Table 2). Per protocol analysis only differed 
from intention to treat with regard to fat free mass in the 
LED + AIT group (Additional file 1: Table S2).
Physical activity
During the first 12  weeks  VO2peakffm improved 
by 11.4% and workload by 10.4% in the AIT group 
(p < 0.002) while both remained unchanged after 
LED [29]. Median training attendance during the last 
40  weeks was 63% (IQ-range 49%; 82%) and 50% (IQ-
range 0%; 70%) in the AIT and LED + AIT group, 
respectively. During the maintenance period there was 
a small but non-significant decrease in all measures 
of physical fitness in the AIT group such that only the 
increase in  VO2peakbw and CPET workload remained 
statistically improved at 1  year (p < 0.027 and 0.017, 
respectively). In the LED + AIT group a significant 
improvement in physical fitness was obtained with 
regard to all measures of physical fitness compared to 
Table 1 Baseline characteristics
Baseline characteristics intention-to-treat population. Categorical data: number (%), normally distributed data: mean (SD), non-normally distributed data: median 
(IQ-range). p-values: between-group differences
AIT, aerobic interval training; LED, low energy diet;  VO2peakbw, peak aerobic capacity corrected for body weight;  VO2peakffm, peak aerobic capacity corrected for 
fat free mass, CCS, Canadian Cardiovascular Society; NYHA, New York Heart Association; ACE-I, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor 
blocker
AIT (n = 26) LED + AIT (n = 29) p
Male 22 (85%) 21 (72%) 0.34
Age 62.3 (5.7) 63.8 (6.7) 0.38
VO2peakffm (mL/kg  ffm
0.67/min) 124 (24) 126 (25) 0.83
VO2peakbw (mL/kg/min) 20.8 (4.9) 20.6 (5.0) 0.85
Body weight (kg) 96.2 (13.8) 95.5 (10.7) 0.85
Body mass index (kg/m2) 31.5 (29.6; 33.5) 31.3 (29.9; 33.7) 0.85
Body fat mass (kg) 32.6 (7.6) 34.6 (8.0) 0.36
Waist circumference (cm) 110 (10) 108 (7) 0.36
Hip circumference (cm) 111 (8) 110 (7) 0.80
Systolic blood pressure (mmHg) 126 (13) 127 (15) 0.78
Diastolic blood pressure (mmHg) 74 (9.2) 71 (7.7) 0.18
Total cholesterol (mmol/L) 4.3 (0.8) 4.1 (0.7) 0.23
Left ventricular ejection fraction (%) 53 (8) 53 (7) 0.97
Pre‑diabetes 21 (81%) 25 (86%) 0.59
Ischaemic aetiology and treatment
 Myocardial infarction 8 (31%) 22 (76%) < 0.001
 Percutaneous coronary intervention 17 (65%) 23 (79%) 0.25
 Coronary artery bypass graft 6 (23%) 6 (21%) 0.83
 Prior cardiac rehabilitation 24 (92%) 21 (72%) 0.06
CCS‑class
 0 21 (81%) 23 (79%)
 I 5 (19%) 6 (21%) 0.89
NYHA‑class
 I 21 (81%) 21 (72%)
 II 5 (19%) 7 (24%) 0.87
 III 0 (0%) 1 (3%)
Medication
 ACE‑I/ARB 15 (58%) 21 (72%) 0.57
 Acetylsalicylic acid 23 (88%) 26 (90%) 1.00
 Beta blocker 12 (46%) 16 (55%) 0.50
 Calcium antagonist 6 (23%) 10 (34%) 0.39
 Statin 25 (96%) 28 (97%) 1.00
 Other cholesterol‑lowering drug 5 (19%) 2 (7%) 0.24
Page 7 of 13Pedersen et al. Cardiovasc Diabetol          (2019) 18:127 
Ta
bl
e 
2 
Bo
dy
 c
om
po
si
ti
on
 a
nd
 p
hy
si
ca
l fi
tn
es
s
In
te
nt
io
n-
to
-t
re
at
 a
na
ly
si
s. 
Ba
se
lin
e:
 m
ea
n 
(S
D
) B
as
el
in
e 
da
ta
 a
re
 p
re
se
nt
ed
 a
s 
m
ea
n 
(S
D
), 
w
ith
in
- a
nd
 b
et
w
ee
n-
gr
ou
p 
di
ffe
re
nc
es
 a
re
 p
re
se
nt
ed
 w
ith
 9
5%
 C
I. 
A
IT
, A
er
ob
ic
 in
te
rv
al
 tr
ai
ni
ng
, L
ED
, L
ow
 e
ne
rg
y 
di
et
, 
 VO
2p
ea
k t
ot
al
, T
ot
al
 p
ea
k 
ae
ro
bi
c 
ca
pa
ci
ty
,  V
O
2p
ea
k b
w
, P
ea
k 
ae
ro
bi
c 
ca
pa
ci
ty
 c
or
re
ct
ed
 fo
r b
od
y 
w
ei
gh
t, 
 VO
2p
ea
k ff
m
, P
ea
k 
ae
ro
bi
c 
ca
pa
ci
ty
 c
or
re
ct
ed
 fo
r f
at
 fr
ee
 m
as
s, 
CP
ET
, C
ar
di
op
ul
m
on
ar
y 
ex
er
ci
se
 te
st
, R
ER
, r
es
pi
ra
to
ry
 
ex
ch
an
ge
 ra
tio
a  
Be
tw
ee
n-
gr
ou
p 
di
ffe
re
nc
e 
at
 1
 y
ea
r c
or
re
ct
ed
 fo
r b
as
el
in
e 
di
ffe
re
nc
e
A
IT
 (n
 = 
26
)
LE
D
 + 
A
IT
 (n
 = 
29
)
Be
tw
ee
n‑
gr
ou
p 
1 
ye
ar
a
p
Ba
se
lin
e
Ch
an
ge
 b
as
el
in
e 
to
 1
 y
ea
r
p
Ch
an
ge
 1
2 
w
ee
ks
 
to
 1
 y
ea
r
p
Ba
se
lin
e
Ch
an
ge
 b
as
el
in
e 
to
 1
 y
ea
r
p
Ch
an
ge
 1
2 
w
ee
ks
 
to
 1
 y
ea
r
p
Bo
dy
 c
om
po
si
tio
n
 W
ei
gh
t (
kg
)
96
.2
 (1
3.
8)
− 
1.
7 
(−
 0
.7
; −
 2
.6
)
<
 0
.0
01
− 
0.
4 
(−
 1
.4
; 0
.6
)
0.
40
6
95
.6
 (1
0.
7)
− 
7.
2 
(−
 8
.4
; −
 6
.1
)
<
 0
.0
 0
1
2.
5 
(1
.3
; 3
.6
)
<
 0
.0
01
5.
6 
(4
.1
; 7
.1
)
<
 0
.0
01
 B
od
y 
m
as
s 
in
de
x 
(k
g/
m
2 )
32
.1
 (3
.2
)
− 
0.
6 
(−
 0
.9
; −
 0
.2
)
0.
00
1
− 
0.
1 
(−
 0
.5
; 0
.2
)
0.
40
8
32
.2
 (3
.1
)
− 
2.
5 
(−
 2
.9
; −
 2
.1
)
<
 0
.0
01
0.
8 
(0
.4
; 1
.2
)
<
 0
.0
01
1.
90
 (1
.3
7;
 2
.4
2)
<
 0
.0
01
 B
od
y 
fa
t m
as
s 
(k
g)
32
.6
 (7
.6
)
− 
1.
9 
(−
 2
.8
; −
 1
.0
)
<
 0
.0
01
− 
0.
3 
(−
 1
.2
; 0
,5
)
0.
44
8
34
.6
 (8
.0
)
− 
6.
6 
(−
 7
.7
; −
 5
.5
)
<
 0
.0
01
1.
9 
(0
.8
; 3
.1
)
<
 0
.0
01
4.
7 
(3
.2
; 6
.2
)
<
 0
.0
01
 B
od
y 
fa
t %
34
.6
 (6
.5
)
− 
1.
5 
(−
 2
.4
; −
 0
.7
)
<
 0
.0
01
0.
2 
(−
 1
.0
; 0
.6
)
0.
61
8
36
.7
 (6
.8
)
− 
4.
7 
(−
 5
.8
; −
 3
.7
)
<
 0
.0
01
1.
6 
(0
.5
; 2
.7
)
0.
00
3
3.
2 
(1
.8
; 4
.6
)
<
 0
.0
01
 F
at
 fr
ee
 m
as
s 
(k
g)
62
.9
 (9
.9
)
0.
2 
(−
 0
.5
; 0
.9
)
0.
56
4
− 
0.
3 
(−
 0
.9
; 0
.4
)
0.
43
0
60
.4
 (8
.8
)
− 
0.
5 
(−
 1
.1
; 0
.0
2)
0.
06
0
0.
3 
(−
 0
.2
; 0
.9
)
0.
24
0
0.
7 
(−
 0
.1
; 1
.6
)
0.
09
6
 W
ai
st
 (c
m
)
10
9.
9 
(9
.5
)
− 
3.
3 
(−
 5
.1
; −
 1
.5
)
<
 0
.0
01
− 
0.
4 
(−
 2
.2
; 1
.4
)
0.
69
6
10
7.
7 
(7
.1
)
− 
6.
6 
(−
 8
.6
; −
 4
.6
)
<
 0
.0
01
3.
2 
(1
.2
; 5
.2
)
0.
00
2
3.
3 
(0
.6
; 6
.1
)
0.
01
8
 H
ip
 (c
m
)
11
0.
8 
(8
.0
)
− 
4.
0 
(−
 5
.1
; −
 2
.9
)
<
 0
.0
01
− 
1.
7 
(−
 2
.8
; −
 0
.6
)
0.
00
3
11
0.
3 
(7
.5
)
− 
6.
0 
(−
 7
.4
; −
 4
.7
)
<
 0
.0
01
0.
9 
(−
 0
.4
; 2
.2
)
0.
20
1
2.
0 
(0
.3
; 3
.8
)
0.
02
5
 W
ai
st
/h
ip
– 
ra
tio
0.
99
 (0
.1
)
0.
00
5 
(−
 0
.0
1;
 0
.0
2)
0.
51
2
0.
01
 (−
 0
.0
03
; 0
.0
3)
0.
11
6
0.
98
 (0
.1
)
− 
0.
01
 (−
 0
.0
3;
 0
.0
1)
0.
39
7
0.
02
 (0
.0
1;
 0
.0
2)
0.
00
8
0.
01
 (−
 0
.0
1;
 0
.0
4)
0.
29
5
Ph
ys
ic
al
 fi
tn
es
s
 V
O
2p
ea
k t
ot
al
 (m
L/
m
in
)
19
97
 (4
63
)
95
 (−
 3
0;
 2
21
)
0.
13
5
− 
12
3 
(−
 2
49
; 2
)
0.
05
3
19
81
 (5
33
)
13
2 
(3
7;
 2
27
)
0.
00
7
19
6 
(1
02
; 2
92
)
<
 0
.0
01
− 
36
 (−
 1
92
; 1
19
)
0.
64
5
 V
O
2p
ea
k k
g 
(m
L/
kg
/m
in
)
20
.8
 (4
.9
)
1.
5 
(0
.2
; 2
.9
)
0.
02
7
− 
1.
0 
(−
 2
.3
; 0
.4
)
0.
15
0
20
.6
 (5
.2
)
3.
1 
(2
.9
; 4
.2
)
<
 0
.0
01
1.
5 
(0
.4
; 2
.7
)
0.
00
7
− 
1.
6 
(−
 3
.3
; 0
.2
)
0.
07
7
 V
O
2p
ea
k ff
m
 (m
L/
kg
 fa
t f
re
e 
 m
as
s0
.6
7 /
m
in
)
12
4.
0 
(2
4.
3)
5.
9 
(−
 1
.9
; 1
3.
7)
0.
13
8
− 
7.
4 
(−
 1
5.
2;
 0
.4
)
0.
06
5
12
5.
5 
(2
5.
2)
8.
7 
(2
.8
; 1
4.
6)
0.
00
4
11
.9
 (6
.0
; 1
7.
9)
<
 0
.0
01
− 
2.
8 
(−
 1
2.
4;
 6
.9
)
0.
57
5
 P
ea
k 
RE
R
1.
19
 (0
.0
8)
0.
00
02
 (−
 0
.0
3;
 0
.0
3)
0.
98
9
0.
01
 (−
 0
.0
2;
 0
.0
4)
0.
60
2
1.
18
 (0
.0
9)
0.
06
 (−
 0
.0
2;
 0
.0
9)
<
 0
.0
01
0.
00
00
1 
(−
 0
.0
3;
 0
.0
3)
0.
99
9
− 
0.
05
 (−
 0
.1
; −
 0
.0
1)
0.
01
8
 M
ax
 w
or
kl
oa
d 
(W
)
15
8 
(4
2)
13
 (2
; 2
3)
0.
01
7
− 
7.
6 
(−
 1
8;
 3
)
0.
15
5
15
5 
(4
8)
15
 (9
; 2
2)
<
 0
.0
01
15
 (9
; 2
2)
<
 0
.0
01
− 
2.
5 
(−
 1
4.
4;
 9
.5
)
0.
68
7
 P
ea
k 
he
ar
t r
at
e
13
7 
(2
3)
1 
(−
 4
; 7
)
0.
63
8
1 
(−
 6
; 5
)
0.
82
6
13
5 
(2
2)
9 
(4
; 1
3)
<
 0
.0
01
9 
(−
 4
; 1
4)
<
 0
.0
01
− 
7.
4 
(−
 1
4.
5;
 −
 0
.3
)
0.
04
0
Page 8 of 13Pedersen et al. Cardiovasc Diabetol          (2019) 18:127 
baseline (Table  2). Per protocol analyses did not dif-
fer from the intention to treat analyses (Additional 
file  1: Table  S2). After 1  year there was no difference 
between the groups in physical fitness variables. One 
participant in each group did not complete the CPET 
due to claustrophobia or hip pain. One participant in 
the LED + AIT group did not attend the CPET at 1 year 
due to recent knee surgery.
At baseline the AIT group seemed to have a higher 
physical activity level than the LED + AIT group (6204 
(4069) kcal/week vs. 4381 (2794) kcal/week though the 
difference was not significant (p = 0.345). At 1  year the 
weekly energy expenditure increased by 2359 kcal/week 
(95% CI 528; 4191, p = 0.012) in the LED + AIT group 
and by 1408 kcal/week (95% CI − 2726; 5542, p = 0.504) 
in the AIT group. These changes resulted in similar 
weekly energy expenditures in the two groups at 1  year 
(p = 0.656).
Lipids and lipoprotein subgroups
The 12-week intervention caused a significant decrease 
in chemically determined total cholesterol, non-HDL-C, 
total cholesterol/HDL-C ratio and triglycerides in both 
groups with no significant between-group differences. 
No changes were seen in HDL-C [29]. After 1  year a 
significant decrease was seen in triglycerides, total and 
non-HDL-C cholesterol in both groups while LDL-C and 
HDL-C remained unchanged. A decrease in total choles-
terol/HDL-C-ratio was only seen after LED + AIT. There 
was no difference between the intention to treat and per 
protocol analyses (Additional file 1: Tables S3 and S4).
Based on density profiling the 12-week intervention 
reduced AUC total lipoprotein and LDL in both groups 
while a shift toward a less atherogenic lipid profile was 
only seen after LED [28]. Decreases in total lipoprotein, 
LDL and HDL AUC in both groups as well as reductions 
in small, dense LDL AUC following weight loss were not 
maintained after 1  year. Reduced triglyceride-rich lipo-
protein persisted only in the LED + AIT group (Fig.  2a, 
Additional file  1: Table  S5). After 1  year LED + AIT 
but not AIT, showed increased HDL particle size and 
induced a shift in the HDL distribution to increase the 
proportion of large HDL subclasses,  HDL2a and  HDL2b 
(Fig. 2b). Furthermore, the contribution of HDL to total 
lipoprotein AUC increased following LED + AIT (base-
line: 56.4%, difference: 2.5% (0.7%; 4.3%) p = 0.005). 
However, no significant between-group differences were 
seen at 1 year. All participants had LDL pattern B (LDL 
particle size ≤ 25 Å) [40] both before and after the inter-
vention. At 1  year there was no difference between the 
intention to treat and per protocol analyses (Additional 
file 1: Table S6).
Inflammatory markers
After 12 weeks there was largely no effect on inflamma-
tory markers in either group except a decrease in TNFα 
following weight loss [28]. After 1  year the AIT group 
obtained a significant 35% (p = 0.019) decrease in CRP 
while TNFα and suPAR remained unchanged. Intention-
to-treat analyses showed a significant decrease following 
LED + AIT in TNFα, suPAR and CRP of 13% (p < 0.001), 
11% (p < 0.001) and 33% (p = 0.040), respectively. In the 
per protocol analyses the 31% decrease in CRP following 
Fig. 2 Change in the distribution of LDL and HDL from baseline 
to 1 year. a Changes baseline to 1 year in the distribution of 
LDL‑subfractions by the change in the proportion that each 
subfraction constitutes of total LDL. b Changes in the distribution 
of HDL‑subfractions by the change in the proportion that each 
subfraction constitutes of total HDL. Error‑bars: 95% CI. Within‑group 
difference: *p < 0.05, ***p ≤ 0.001. No between‑group differences 
were seen. AIT aerobic interval training, LED low energy diet, LDL low 
density lipoprotein, HDL high density lipoprotein
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AIT + LED was statistically non-significant (p = 0.081). 
This was possibly due to a smaller sample size. After 
1  year a significant between-group difference was seen 
regarding suPAR (p = 0.036) (Additional file 1: Tables S7 
and S8).
Blood pressure and HADS
We observed no changes in blood pressure after 
12  weeks’ intervention but there is a possible trend 
towards a reduction of these values. Moreover, six par-
ticipants had their antihypertensive treatment reduced 
following LED [29]. No significant changes were seen in 
blood pressure after the one-year intervention. Exclud-
ing four patients with changes in their medication did not 
affect the conclusion. Following the 12-week intervention 
a slight improvement was seen in HADS-A [29] while no 
overall significant changes was seen after 1  year in nei-
ther HADS-A nor HADS-D (data not shown).
Discussion
In this randomised study we compared a combination of 
weight loss and interval training with interval training 
alone during a 1-year intervention in overweight, sed-
entary CAD patients. The main findings were a similar 
improvement in exercise capacity in the two groups while 
the combined intervention achieved superior improve-
ments in body composition. After 1  year both groups 
obtained a decrease in total cholesterol, non-HDL cho-
lesterol and triglycerides while total cholesterol/HDL 
ratio was only decreased after LED + AIT. The effects 
on LDL particle size and atherogenicity were limited in 
both groups; however, a shift toward larger more buoy-
ant HDL particles and an increase in the proportion of 
total lipoprotein constituted by HDL was seen follow-
ing LED + AIT. Low-grade inflammation as indicated by 
CRP was reduced in both groups but TNFα and suPAR 
were only reduced in the LED + AIT group.
A recent survival analyses including participants with-
out cardiovascular disease examine the interplay between 
characteristics of physical activity and cardiovascular dis-
ease prevention in nine subgroups divided by cardiovas-
cular risk based on e.g. insulin resistance, hypertension, 
weight and dyslipidaemia. They conclude that physical 
activity with increased energy expenditure is associated 
with cardiovascular disease prevention but only in the 
low-risk subgroups. Hence, the beneficial effect of physi-
cal activity in high-risk subgroups is attenuated. How-
ever, the registered physical activity level was low in the 
high-risk subgroups overall making generalisability dif-
ficult [41]. Previous interventional studies addressing 
lifestyle changes have mainly included healthy individu-
als and excluded participants with pre-existing CAD or 
CVD. The current trial includes overweight, sedentary 
individuals with CAD and insulin resistance resembling 
the population described in the EUROASPIRE cohort [5].
A Cochrane review found that exercise-based cardiac 
rehabilitation programmes lower hospital admissions, 
total and cardiovascular mortality [4] and observational 
studies show that impaired peak aerobic capacity is a 
strong predictor of mortality in CAD patients [42]. Few 
interventional studies have described the effect of life-
style changes on hard cardiovascular end-points. How-
ever, the 2013 the Look AHEAD trial that include 5145 
participants with type 2 diabetes, showed that despite an 
improved cardiovascular risk profile and glycaemic con-
trol there was no difference in cardiovascular mortality 
between usual care and intensive lifestyle change after a 
median follow-up period of 9.6 years. Notably, the partic-
ipants undergoing lifestyle changes had difficulty sustain-
ing the initial improvements obtained [43]. The current 
trial was not designed or powered to address hard cardio-
vascular end-points.
Physical fitness and body composition
Our findings on physical fitness agree with two ear-
lier studies. A study from 2011 included 93 healthy, 
obese participants undergoing 1  year of either exercise, 
diet induced weight loss or a combined diet and exer-
cise intervention [30]. A smaller 2006 study compared 
6  months’ combined exercise and weight loss to a no 
therapy control group [44, 45]. In both of those stud-
ies the combined interventions improved physical per-
formance and  VO2peak (mL/kg/min). In the trial from 
2011 the combined intervention was superior to the 
other interventional groups with within-group differ-
ences similar to the present trial. In interventional stud-
ies marked changes in body weight introduce a bias when 
using  VO2peakbw to describe physical fitness. There-
fore, the values for  VO2peak adjusted for body weight 
reported in 2011 may have been overestimated by lack 
of adjustment for the greater weight loss [30]. We calcu-
lated  VO2peakffm (mL/kg fat free  mass0.67/min) because 
energy expenditure during exercise is primarily in muscle 
tissue and  VO2peakffm provides a fitness estimate that is 
independent of body weight [36]. Using this approach the 
LED + AIT intervention still elicited a larger increase in 
physical fitness at 1 year; however, there was no signifi-
cant difference between the groups on any of the physical 
fitness variables (Table 2). Based on the iPAQ question-
naires the LED + AIT group had a greater increase in 
their weekly energy expenditure possibly explaining the 
increase in  VO2peak despite a lower training attend-
ance than the AIT group. However, the iPAQ results 
are subject to some uncertainty as reflected by the large 
Page 10 of 13Pedersen et al. Cardiovasc Diabetol          (2019) 18:127 
confidence intervals; moreover, there was no between-
group difference after 1 year when correcting for baseline 
values.
The improvements in body composition observed in 
the current trial correspond well to those reported in 
the two interventional trials cited above [30, 45] except 
for significant losses of fat free mass after the combined 
weight loss and exercise interventions. Nonetheless, 
in the 2011 trial the loss of fat free mass induced by the 
combined diet and exercise intervention was smaller than 
in the diet group (1.8 and 3.2 kg, respectively). In a ran-
domised trial an approximate 10 kg weight loss induced 
by either caloric restriction or exercise only the exercise 
group maintained lower extremity muscle size and abso-
lute strength [46]. Even though the loss of fat free mass 
was limited after LED in the present trial [29], weight loss 
interventions without exercise introduce a risk of los-
ing lean body mass. This is an important consideration 
when designing cardiac rehabilitation programme, since 
low lean body mass is related to increased mortality in 
CAD [47]. A recent systematic review and meta-analysis 
showed that healthy individuals with the metabolic syn-
drome obtain improvements in body composition, meta-
bolic and cardiovascular risk factors like those seen after 
AIT in the present trial [25]. Even though exercise alone 
only leads to a small weight loss a concomitant decreases 
in waist circumference is often seen as in the present trial 
[25]. Abdominal obesity is related to increased mortality 
in CAD [3]. In the current trial we showed a significant 
decrease in waist circumference and visceral abdomi-
nal fat after 12  weeks’ AIT [29]. The decrease in waist 
circumference persisted after 1 year (Table 2). It is well-
described that visceral adipose tissue is linked to insulin 
resistance, dyslipidaemia and low-grade inflammation 
[48]. In addition, a recent Norwegian study show that 
12 weeks’ exercise elicit a normalisation of macrophage-
related mRNA transcript levels in subcutaneous white 
adipose tissue. This was closely related to improved 
insulin sensitivity in overweight, sedentary, dysglycae-
mic men and suggest that subcutaneous adipose tissue 
could also be an important mediator of exercise-induced 
decreases in the inflammatory response and improve-
ments in insulin sensitivity delaying the development of 
type 2 diabetes [49].
Lipids and density profiling
After 1  year a significant decrease in chemically deter-
mined total cholesterol, non-HDL-C and triglycerides 
was observed in both groups while LDL-C and HDL-C 
remained unchanged. A decrease in total cholesterol/
HDL-C-ratio was only seen after LED + AIT. Density 
profiling was used to provide additional information on 
lipoprotein particle density and subclass distribution. 
The main finding was a shift in HDL subclass distribu-
tion and increased HDL particle size in the LED + AIT 
group while no changes were seen following AIT alone. 
The limited effect seen following exercise differs from 
outcomes from a recent meta-analysis comprising six tri-
als, with a total of 1555 participants without CAD and 
10 different exercise interventions [18]. That analysis 
found that exercise resulted in a shift toward larger LDL 
and HDL particles. The total amount of exercise in our 
trial was possibly insufficient to achieve similar effects 
on particle size. Overall, the exercise interventions in the 
meta-analysis lasted 20–35  weeks, the intensities were 
generally lower than in the current trial while the weekly 
amount of time spent exercising was higher. Addition-
ally, some methodological differences may occur, since 
particle size in the meta-analyses was determined using 
nuclear magnetic resonance spectroscopy, while it was 
calculated from density distributions in the current trial. 
In the STRRIDE study, participants who underwent 
8  months’ high-amount of high-intensity exercise train-
ing obtained a shift toward larger HDL and LDL parti-
cles while the effects of a low amount of high-intensity 
exercise were less pronounced [19]. Two previous stud-
ies comparing weight loss induced by either exercise or 
diet also found varying effects on LDL and HDL levels 
and particle size [16, 17]. As in the current trial, the pop-
ulations in those studies were small (15–47 participants 
in each group) and some of the discrepancies could be 
related to sample size. In the present trial all participants 
exhibited a preponderance of small dense LDL particles, 
the so called LDL pattern B throughout the study [40]. 
The inability to maintain the improvements in LDL dis-
tribution and particle size obtained after LED could be 
due to return to neutral or even positive energy balance. 
Furthermore, the participants in LED + AIT group sta-
bilised their BMI at ~ 30  kg/m2. An interventional trial 
including 100 participants showed that BMI < 25  kg/m2 
was required to convert LDL pattern B to LDL pattern 
A [50] suggesting that the weight loss in the present trial 
may not have been sufficient. Finally, participants in the 
present study were contemporarily treated with statins. 
Since statins have been shown to decrease LDL levels and 
increase HDL and LDL particle size this could attenuate 
the effect of the intervention compared with a healthy, 
statin naïve population [51, 52].
Inflammatory markers
During the first 12  weeks changes in markers of low-
grade inflammation was limited in both groups [28]. 
However, more distinct effects on CRP, TNFα and suPAR 
were seen after 1 year. In observational studies elevated 
levels of CRP, TNFα and suPAR were associated with 
a poor prognosis in CAD [13–15] suggesting that the 
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decreases in low-grade inflammation obtained in the pre-
sent study might improve the participants’ prognosis. The 
reduced CRP-levels following 1 year of AIT corresponds 
well to a meta-analysis including 23 interventional stud-
ies demonstrating that exercise training is associated 
with reduced CRP-levels in CAD patients [21]. The lack 
of effect on TNFα after 1 year of AIT agrees with a study 
of 12 patients with ischaemic heart failure undergoing 
4  months’ exercise training that showed no change in 
TNFα [53]. However, soluble TNF1- and TNF2-receptors 
were decreased significantly in these same subjects sug-
gesting an attenuated inflammatory response. Moreover, 
an eight-week exercise-based cardiac rehabilitation pro-
gramme elicited no reduction in neither TNFα nor CRP 
in 96 CAD patients despite improved  VO2peak corrected 
for body weight [20]. Our findings that CRP was reduced 
1 year of AIT suggests that duration of exercise is impor-
tant. In the present trial CRP did not change significantly 
after the first 12 weeks’ exercise [28] and a small Russian 
study that compared 8 weeks’ moderate intensity training 
with high intensity interval training in overweight and 
obese young adults even found an increase in CRP fol-
lowing high intensity exercise [54]. An acute increase in 
CRP has been seen immediately after exercise [55]; how-
ever, in the Russian trial blood samples were drawn > 48 h 
after the last exercise session [54]. Few studies have 
described the effects of a long-term intervention and 
the studies included in the meta-analyses cited above 
had only 3–24 weeks’ exercise and lifestyle intervention 
[21]. Regarding weight loss our results are supported by 
a review comprising 33 interventional studies concluding 
that CRP is reduced after weight loss in a healthy popu-
lation [22]. In the DIOGenes trial the group undergoing 
8 weeks’ of LED followed by 26 weeks’ high protein, low 
glycaemic load diet obtained a decrease in CRP similar 
to our results [56]. The concurrent decrease in TNFα and 
suPAR following LED + AIT suggests an overall decrease 
in low-grade inflammation.
Notably, there is a significant between-group differ-
ence in suPAR levels after 1  year. Studies addressing 
the effects of lifestyle interventions on suPAR levels are 
sparse; however, a recent randomised trial including 133 
healthy participants undergoing 5 months’ exercise inter-
vention obtained no effect on suPAR levels supporting 
our findings [57]. In addition, observational data in 5538 
individuals showed no relationship between self-reported 
leisure-time physical activity and suPAR levels when 
adjusting for lifestyle and cardiovascular risk factors [58]. 
In both studies an association between BMI and suPAR 
levels was seen [57, 58] possibly explaining the effect of 
weight loss, but not exercise, on suPAR levels. However, 
this conclusion is not certain since another observational 
study of 2273 individuals without cardiovascular disease 
reported it findings. That study found that suPAR was 
only positively related to BMI and waist circumference in 
female smokers, while a negative association was seen in 
non-smoking men and women [59]. Thus, further studies 
are needed to establish the relationship between physical 
activity, body weight and suPAR.
Strengths and limitations
This randomised trial addresses both the effects of an 
intensive lifestyle intervention as published previously 
[28, 29] and the participants ability to maintain the 
improvements achieved in physical fitness and metabolic 
risk as presented in the current paper. Both interven-
tions were feasible, and the participants were well-mon-
itored by dieticians and physiotherapists. However, when 
applying the results to rehabilitation programmes selec-
tion bias and generalisability must be considered. The 
enrolled participants could be more motivated to engage 
in lifestyle changes than the CAD population in general. 
Transferring the results to individuals with co-mor-
bidities covered by the exclusion criteria e.g. diabetes, 
chronic obstructive pulmonary disease and severe heart 
failure should be done carefully.
Drop-out rates (26% and 17% in the AIT and 
LED + AIT group, respectively) imply that intensive life-
style changes require physical and mental strength and 
support from relatives and employers especially when 
considering long-term interventions. In addition, eight 
participants in the LED + AIT group followed the main-
tenance diet but did not participate in the exercise train-
ing. Our main analysis included all participants who 
attended the baseline visit and both follow-up visits irre-
spective of adherence to protocol. However, drop-out 
rates introduce a risk of bias due to small sample size and 
challenges related to generalisability as discussed above. 
Sample size calculations showed that 26 participants 
were required in each group; thus anticipating 25% drop-
out we included 70 participants [35].
Despite randomisation a significant baseline differ-
ence regarding previous MI was seen. However, all par-
ticipants had stable CAD diagnosed > 6 months prior to 
inclusion. The groups were similar regarding symptoms, 
risk factors, medication and left ventricular ejection frac-
tion (Table 1) and are considered comparable.
Conclusion
In this sedentary, overweight population with CAD, 
dyslipidaemia and insulin resistance the interventions 
resulted in similar improvements in physical fitness, 
serum-lipids and inflammation. The combination of diet 
and exercise as an intervention was superior in achiev-
ing long-term improvements in body composition. This 
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suggests that a programme including both caloric restric-
tion and exercise can be recommended in CAD reha-
bilitation to reduce cardiovascular and metabolic risk 
factors.
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